Related Experiment Video
Updated: Dec 11, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.9K
Small-molecule GLP-1 secretagogs: challenges and recent advances
1Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.
Drug Discovery Today
|August 25, 2020
Summary
Small molecules that stimulate glucagon-like peptide-1 (GLP-1) secretion offer a promising alternative to existing diabetes treatments. This review highlights recent advancements in discovering these small-molecule GLP-1 secretagogs targeting G-protein-coupled receptors.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Drug Discovery
Background:
- Glucagon-like peptide-1 (GLP-1) is a key hormone for managing type 2 diabetes mellitus (T2DM) due to its anti-hyperglycemic effects.
- GLP-1's glucose-dependent action prevents hypoglycemia, making it a safer alternative to some diabetes medications.
- Current treatments primarily involve GLP-1 peptide analogs, but research into small-molecule secretagogs is ongoing.
Purpose of the Study:
- To review recent progress in the discovery of small-molecule compounds that stimulate GLP-1 secretion.
- To focus on small molecules targeting the G-protein-coupled receptor (GPCR) family for GLP-1 release.
- To discuss the challenges and future strategies in developing small-molecule GLP-1 secretagogs.
Main Methods:
- Literature review of recent scientific publications on small-molecule GLP-1 secretagogs.
- Analysis of studies focusing on G-protein-coupled receptor (GPCR) targets for GLP-1 stimulation.
- Synthesis of information regarding drug discovery challenges and advancements.
Main Results:
- Several classes of small molecules targeting GPCRs have shown potential in stimulating GLP-1 secretion.
- Advances in understanding GPCR signaling pathways have facilitated the identification of novel drug targets.
- Challenges remain in optimizing efficacy, safety, and pharmacokinetic properties of these small molecules.
Conclusions:
- Small-molecule GLP-1 secretagogs represent a promising therapeutic avenue for type 2 diabetes mellitus.
- Targeting GPCRs is a key strategy in the development of novel small-molecule secretagogs.
- Continued research and development are crucial to overcome existing challenges and bring these therapies to clinical practice.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
677
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
677
01:06Oral Hypoglycemic Agents: Glinides
472
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
472
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
436
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
436
01:23Dipeptidyl Peptidase 4 Inhibitors
434
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
434
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
503
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
503
01:17Oral Hypoglycemic Agents: Sulfonylureas
611
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
611